Answers are grounded in this paper and cite their sources.
Clinical E. coli isolates (36) from women (aged 18-45 years) with symptomatic genital tract infection were detected phenotypically and genotypically for ESBL production. Phenotypically, most (30/36: 83.3%) isolates were resistant to cefotaxime (CTX) and more than half of them (26/36: 72.2%) were resistant to ceftazidime (CAZ). All (100%) and 25 (69.4%) of them were ESBLs producers by screening and confirmatory tests, respectively. Genotypically, ESBL genotypes were detected in 31/36 (86.1%) of isolates. All four ESBL genotypes were found among these isolates with predominance of CTX-M-type (26/36: 72.2%) followed by SHV-type (22/36: 61.1%), OXA-type (7/36: 19.4%), and TEM-type (1/36: 2.7%). Of These isolates, 25/36 (69.4%) had two types of ESBL genes. Seventeen (17/22: 77.2%) of SHV-type positive isolates were CTX-M positive. Six (6/7: 85.7%) of OXA-type and the TEM-type positives were also CTX-M- positive whereas the other OXA-type positive isolate was SHV-type positive. Most (22/25: 88%) isolates with two types of ESBLs were resistant to both CTX and CAZ. It can be concluded that, in female's genital tract infection, ESBL production, especially CTX-M-type, can be added as another factor, in addition to virulence factors, that select for certain strains to survive and cause disease and as vaginal E. coli is a reservoir along the fecal-vaginal-urinary/neonatal course of transmission in extraintestinal E. coli infections, our clinicalmicrobiology labs and clinicians need to be aware of the presence of these ESBL-producing organisms and should conduct surveillance studies to ascertain this.
No takes yet. Share an insight, caveat, or question.
Ahmed Darwish Jabbar (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: